Key terms
About ATHE
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATHE news
Yesterday
8:57pm ET
Alterity Therapeutics Expands Securities Quotation
Yesterday
10:45am ET
Biotech Alert: Searches spiking for these stocks today
Apr 12
8:27am ET
Alterity Therapeutics Shareholders Approve Resolutions
Apr 12
8:27am ET
Alterity Therapeutics’ Resolutions Pass Unanimously
Mar 26
8:57am ET
Alterity Therapeutics Secures $3.9M R&D Refund
Feb 21
5:41pm ET
Alterity Therapeutics Ltd (ADR) trading halted, news pending
Feb 06
7:32am ET
Alterity Therapeutics says Phase 2 DMC recommends continuation of trial
Jan 22
7:29am ET
Alterity Therapeutics expects preliminary data from ATH434-202 study in 1H24
No recent press releases are available for ATHE
ATHE Financials
Key terms
Ad Feedback
ATHE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATHE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
